Latest Insider Transactions at Apellis Pharmaceuticals, Inc. (APLS)
This section provides a real-time view of insider transactions for Apellis Pharmaceuticals, Inc. (APLS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Apellis Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Apellis Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 21
2021
|
Mark Jeffrey De Long Chief Business & Strat Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+8.7%
|
$15,000
$15.52 P/Share
|
|
Jul 15
2021
|
Alec Machiels Director |
SELL
Open market or private sale
|
Direct |
2,500
-0.37%
|
$155,000
$62.3 P/Share
|
|
Jul 15
2021
|
Alec Machiels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+0.37%
|
$5,000
$2.67 P/Share
|
|
Jul 15
2021
|
Mark Jeffrey De Long Chief Business & Strat Officer |
SELL
Open market or private sale
|
Direct |
1,000
-9.53%
|
$62,000
$62.3 P/Share
|
|
Jul 15
2021
|
Mark Jeffrey De Long Chief Business & Strat Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+8.7%
|
$15,000
$15.52 P/Share
|
|
Jul 14
2021
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
500
-0.79%
|
$32,000
$64.68 P/Share
|
|
Jul 08
2021
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
250
-0.39%
|
$16,250
$65.68 P/Share
|
|
Jul 01
2021
|
Nicole D Perry Vice President - Accounting |
SELL
Open market or private sale
|
Direct |
1,000
-17.1%
|
$64,000
$64.0 P/Share
|
|
Jul 01
2021
|
Nicole D Perry Vice President - Accounting |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+14.6%
|
$3,000
$3.76 P/Share
|
|
Jun 28
2021
|
Federico Grossi Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,000
+12.34%
|
$27,000
$3.76 P/Share
|
|
Jun 24
2021
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,250
-0.71%
|
$406,250
$65.61 P/Share
|
|
Jun 24
2021
|
Pascal Deschatelets Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,250
+0.71%
|
$12,500
$2.67 P/Share
|
|
Jun 21
2021
|
David O. Watson General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
489
+0.5%
|
$1,956
$4.31 P/Share
|
|
Jun 15
2021
|
Mark Jeffrey De Long Chief Business & Strat Officer |
SELL
Open market or private sale
|
Direct |
4,000
-29.65%
|
$256,000
$64.96 P/Share
|
|
Jun 15
2021
|
Mark Jeffrey De Long Chief Business & Strat Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+22.87%
|
$60,000
$15.52 P/Share
|
|
Jun 15
2021
|
Alec Machiels Director |
SELL
Open market or private sale
|
Direct |
2,500
-0.37%
|
$160,000
$64.83 P/Share
|
|
Jun 15
2021
|
Alec Machiels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+0.37%
|
$5,000
$2.67 P/Share
|
|
Jun 14
2021
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
500
-0.9%
|
$30,500
$61.84 P/Share
|
|
Jun 11
2021
|
Nicole D Perry Vice President - Accounting |
SELL
Open market or private sale
|
Direct |
1,000
-17.1%
|
$61,000
$61.55 P/Share
|
|
Jun 11
2021
|
Nicole D Perry Vice President - Accounting |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+14.6%
|
$3,000
$3.2 P/Share
|
|
Jun 10
2021
|
Lukas Scheibler Chief Research Officer |
SELL
Open market or private sale
|
Direct |
3,417
-11.36%
|
$205,020
$60.0 P/Share
|
|
Jun 08
2021
|
Timothy Eugene Sullivan Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
39,880
+34.98%
|
$398,800
$10.03 P/Share
|
|
Jun 01
2021
|
Nicole D Perry Vice President - Accounting |
SELL
Open market or private sale
|
Direct |
1,000
-17.1%
|
$56,000
$56.4 P/Share
|
|
Jun 01
2021
|
Nicole D Perry Vice President - Accounting |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+14.6%
|
$3,000
$3.76 P/Share
|
|
Jun 01
2021
|
A. Sinclair Dunlop Director |
BUY
Other acquisition or disposition
|
Indirect |
2,682
+0.88%
|
-
|
|
Jun 01
2021
|
A. Sinclair Dunlop Director |
BUY
Other acquisition or disposition
|
Direct |
13,108
+15.2%
|
-
|
|
Jun 01
2021
|
A. Sinclair Dunlop Director |
SELL
Other acquisition or disposition
|
Indirect |
31,855
-100.0%
|
-
|
|
May 28
2021
|
David O. Watson General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
489
+0.5%
|
$1,956
$4.31 P/Share
|
|
May 24
2021
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,250
-0.71%
|
$293,750
$47.4 P/Share
|
|
May 24
2021
|
Pascal Deschatelets Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,250
+0.71%
|
$12,500
$2.67 P/Share
|
|
May 20
2021
|
A. Sinclair Dunlop Director |
SELL
Open market or private sale
|
Indirect |
5,773
-15.34%
|
$277,104
$48.1 P/Share
|
|
May 19
2021
|
A. Sinclair Dunlop Director |
SELL
Open market or private sale
|
Indirect |
7,612
-2.47%
|
$380,600
$50.0 P/Share
|
|
May 18
2021
|
A. Sinclair Dunlop Director |
SELL
Open market or private sale
|
Indirect |
149,488
-18.35%
|
$7,922,864
$53.17 P/Share
|
|
May 18
2021
|
Mark Jeffrey De Long Chief Business & Strat Officer |
SELL
Open market or private sale
|
Direct |
2,000
-17.41%
|
$110,000
$55.0 P/Share
|
|
May 18
2021
|
Mark Jeffrey De Long Chief Business & Strat Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+14.83%
|
$30,000
$15.52 P/Share
|
|
May 14
2021
|
Alec Machiels Director |
SELL
Open market or private sale
|
Direct |
2,500
-0.37%
|
$112,500
$45.39 P/Share
|
|
May 14
2021
|
Alec Machiels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+0.37%
|
$5,000
$2.67 P/Share
|
|
May 14
2021
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
500
-0.89%
|
$22,500
$45.39 P/Share
|
|
May 03
2021
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
600
-1.07%
|
$30,000
$50.73 P/Share
|
|
May 03
2021
|
Nicole D Perry Vice President - Accounting |
SELL
Open market or private sale
|
Direct |
1,000
-17.1%
|
$50,000
$50.73 P/Share
|
|
May 03
2021
|
Nicole D Perry Vice President - Accounting |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+14.6%
|
$3,000
$3.76 P/Share
|
|
Apr 30
2021
|
Nicole D Perry Vice President - Accounting |
SELL
Open market or private sale
|
Direct |
1,000
-17.1%
|
$50,000
$50.0 P/Share
|
|
Apr 30
2021
|
Nicole D Perry Vice President - Accounting |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+14.6%
|
$3,000
$3.76 P/Share
|
|
Apr 28
2021
|
Pascal Deschatelets Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,500
+0.51%
|
$9,000
$2.67 P/Share
|
|
Apr 23
2021
|
A. Sinclair Dunlop Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+14.29%
|
$140,000
$14.0 P/Share
|
|
Apr 23
2021
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,250
-0.72%
|
$287,500
$46.13 P/Share
|
|
Apr 23
2021
|
Pascal Deschatelets Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,250
+0.71%
|
$12,500
$2.67 P/Share
|
|
Apr 22
2021
|
David O. Watson General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
489
+0.5%
|
$1,956
$4.31 P/Share
|
|
Apr 21
2021
|
Alec Machiels Director |
SELL
Open market or private sale
|
Direct |
2,500
-0.37%
|
$112,500
$45.76 P/Share
|
|
Apr 21
2021
|
Alec Machiels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+0.37%
|
$5,000
$2.67 P/Share
|